See more : Versity (MLVSY.PA) Income Statement Analysis – Financial Results
Complete financial analysis of STAAR Surgical Company (STAA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of STAAR Surgical Company, a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
You may be interested
- 7C Solarparken AG (HRPK.DE) Income Statement Analysis – Financial Results
- IDBI Bank Limited (IDBI.BO) Income Statement Analysis – Financial Results
- Kerry Properties Limited (0683.HK) Income Statement Analysis – Financial Results
- Jindal Saw Limited (JINDALSAW.BO) Income Statement Analysis – Financial Results
- Alfa, S. A. B. de C. V. (ALFFF) Income Statement Analysis – Financial Results
STAAR Surgical Company (STAA)
About STAAR Surgical Company
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone cataract intraocular lenses and injector systems for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 322.42M | 284.39M | 230.47M | 163.46M | 150.19M | 123.95M | 90.61M | 82.43M | 77.12M | 74.99M | 72.22M | 63.78M | 62.77M | 54.96M | 75.35M | 74.89M | 59.36M | 56.28M | 51.30M | 51.69M | 50.46M | 48.25M | 50.24M | 53.99M | 59.00M | 54.20M | 42.50M | 42.20M | 34.70M | 27.40M | 20.10M | 10.20M | 4.30M | 4.50M | 4.50M | 6.80M |
| Cost of Revenue | 69.76M | 61.01M | 51.84M | 45.10M | 38.23M | 32.44M | 26.33M | 24.06M | 24.40M | 26.16M | 21.91M | 19.49M | 20.40M | 19.88M | 33.45M | 34.79M | 30.10M | 29.85M | 27.52M | 25.54M | 22.62M | 24.10M | 28.20M | 22.60M | 18.70M | 14.10M | 6.80M | 7.90M | 6.90M | 4.80M | 3.10M | 2.40M | 2.00M | 2.00M | 7.20M | 8.00M |
| Gross Profit | 252.65M | 223.38M | 178.64M | 118.36M | 111.95M | 91.51M | 64.28M | 58.37M | 52.72M | 48.82M | 50.31M | 44.29M | 42.37M | 35.08M | 41.89M | 40.11M | 29.27M | 26.43M | 23.79M | 26.14M | 27.84M | 24.15M | 22.03M | 31.39M | 40.30M | 40.10M | 35.70M | 34.30M | 27.80M | 22.60M | 17.00M | 7.80M | 2.30M | 2.50M | -2.70M | -1.20M |
| Gross Profit Ratio | 78.36% | 78.55% | 77.51% | 72.41% | 74.54% | 73.83% | 70.94% | 70.81% | 68.36% | 65.11% | 69.67% | 69.44% | 67.50% | 63.82% | 55.60% | 53.55% | 49.30% | 46.97% | 46.36% | 50.58% | 55.17% | 50.05% | 43.86% | 58.14% | 68.31% | 73.99% | 84.00% | 81.28% | 80.12% | 82.48% | 84.58% | 76.47% | 53.49% | 55.56% | -60.00% | -17.65% |
| Research & Development | 44.40M | 35.98M | 33.86M | 31.92M | 25.30M | 22.03M | 19.12M | 20.29M | 14.76M | 12.36M | 6.71M | 6.44M | 5.87M | 5.72M | 5.89M | 7.94M | 6.71M | 7.08M | 5.57M | 6.25M | 5.12M | 4.02M | 3.80M | 4.22M | 4.30M | 3.60M | 3.90M | 4.10M | 3.30M | 2.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 72.32M | 54.74M | 44.14M | 33.91M | 29.31M | 24.29M | 20.67M | 22.25M | 19.60M | 18.48M | 18.81M | 17.79M | 15.99M | 14.08M | 15.71M | 15.73M | 12.95M | 9.34M | 9.34M | 9.34M | 9.34M | 0.00 | 8.75M | 8.59M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 107.83M | 88.86M | 67.29M | 45.76M | 45.49M | 38.60M | 28.13M | 28.48M | 23.70M | 25.88M | 23.89M | 21.28M | 17.73M | 17.18M | 24.26M | 27.05M | 23.72M | 19.51M | 19.51M | 19.51M | 19.51M | 0.00 | 20.04M | 21.25M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 180.15M | 143.60M | 111.44M | 79.68M | 74.80M | 62.89M | 48.80M | 50.73M | 43.30M | 44.36M | 42.70M | 39.07M | 33.72M | 31.25M | 39.97M | 42.78M | 36.67M | 33.29M | 29.03M | 30.06M | 29.24M | 25.79M | 28.79M | 43.62M | 27.80M | 25.50M | 19.00M | 17.80M | 15.90M | 13.10M | 14.20M | 11.60M | 12.90M | 6.10M | 0.00 | 0.00 |
| Other Expenses | 0.00 | 1.26M | 967.00K | 396.00K | 703.00K | 715.00K | 628.00K | 470.00K | 759.00K | 381.00K | 486.00K | 822.00K | 0.00 | 700.00K | -238.00K | 9.77M | 0.00 | -331.00K | 0.00 | 0.00 | 0.00 | 1.45M | 0.00 | 3.73M | 4.20M | 4.40M | 3.50M | 2.30M | 1.50M | 1.30M | 900.00K | 800.00K | 600.00K | 500.00K | 900.00K | 1.50M |
| Operating Expenses | 224.55M | 179.58M | 145.30M | 111.59M | 100.10M | 84.92M | 67.91M | 71.02M | 58.06M | 56.85M | 49.61M | 45.51M | 39.59M | 37.68M | 45.62M | 60.49M | 43.39M | 40.04M | 34.60M | 36.30M | 34.36M | 31.26M | 32.59M | 51.57M | 36.30M | 33.50M | 26.40M | 24.20M | 20.70M | 17.10M | 15.10M | 12.40M | 13.50M | 6.60M | 900.00K | 1.50M |
| Cost & Expenses | 294.32M | 240.59M | 197.13M | 156.69M | 138.33M | 117.36M | 94.24M | 95.09M | 82.46M | 83.01M | 71.52M | 65.00M | 59.98M | 57.56M | 79.07M | 95.28M | 73.48M | 69.88M | 62.12M | 61.84M | 56.98M | 55.36M | 60.79M | 74.17M | 55.00M | 47.60M | 33.20M | 32.10M | 27.60M | 21.90M | 18.20M | 14.80M | 15.50M | 8.60M | 8.10M | 9.50M |
| Interest Income | 0.00 | 2.45M | 38.00K | 238.00K | 988.00K | 165.00K | 0.00 | 3.00K | 50.00K | 51.00K | 59.00K | 59.00K | 32.00K | 43.00K | 60.00K | 160.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 270.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 2.45M | 0.00 | 0.00 | 0.00 | 165.00K | 0.00 | 115.00K | 128.00K | 154.00K | 170.00K | 291.00K | 523.00K | 896.00K | 1.33M | 901.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 5.12M | 4.51M | 3.64M | 3.10M | 3.70M | 2.46M | 3.35M | 2.89M | 2.40M | 2.46M | 2.15M | 1.96M | 2.27M | 2.41M | 3.74M | 3.64M | 2.51M | 2.37M | 2.47M | 2.69M | 2.90M | 3.10M | 3.62M | 3.73M | 4.20M | 4.40M | 3.50M | 2.30M | 1.50M | 1.30M | 900.00K | 800.00K | 600.00K | 500.00K | 900.00K | 1.50M |
| EBITDA | 33.22M | 48.31M | 36.98M | 9.86M | 15.55M | 9.06M | -277.00K | -9.66M | -3.08M | -5.14M | 3.44M | 1.75M | 5.49M | -379.00K | 364.00K | -17.13M | -12.19M | -10.88M | -7.32M | -7.34M | -3.62M | -4.01M | -6.93M | -16.45M | 8.20M | 11.00M | 12.80M | 12.40M | 8.60M | 6.80M | 2.80M | -3.80M | -10.60M | -3.60M | -2.70M | -1.20M |
| EBITDA Ratio | 10.30% | 17.59% | 17.33% | 5.51% | 10.70% | 7.98% | -1.21% | -11.27% | -2.76% | -6.85% | 4.70% | 2.54% | 8.10% | -0.28% | 0.10% | -22.15% | -18.54% | -20.45% | -17.06% | -14.63% | -6.12% | -4.81% | 1.54% | -21.19% | 13.39% | 19.00% | 23.06% | 27.96% | 23.05% | 21.90% | 10.45% | -63.73% | -244.19% | -313.33% | -60.00% | -19.12% |
| Operating Income | 28.10M | 43.80M | 33.34M | 6.77M | 11.85M | 6.60M | -3.63M | -12.66M | -5.34M | -8.03M | 700.00K | -1.22M | 2.78M | -2.60M | -3.73M | -20.39M | -14.12M | -13.60M | -10.81M | -10.16M | -6.53M | -7.11M | -17.79M | -20.18M | 4.00M | 6.60M | 9.30M | 10.10M | 7.10M | 5.50M | 1.90M | -4.60M | -11.20M | -4.10M | -3.60M | -2.70M |
| Operating Income Ratio | 8.71% | 15.40% | 14.47% | 4.14% | 7.89% | 5.32% | -4.01% | -15.35% | -6.92% | -10.70% | 0.97% | -1.91% | 4.43% | -4.73% | -4.95% | -27.22% | -23.78% | -24.17% | -21.07% | -19.65% | -12.93% | -14.74% | -35.40% | -37.38% | 6.78% | 12.18% | 21.88% | 23.93% | 20.46% | 20.07% | 9.45% | -45.10% | -260.47% | -91.11% | -80.00% | -39.71% |
| Total Other Income/Expenses | 5.60M | 1.75M | -2.04M | 1.50M | 1.17M | 44.00K | 1.34M | 211.00K | -268.00K | -618.00K | 414.00K | 701.00K | -79.00K | -1.08M | -741.00K | -1.29M | -1.04M | 95.00K | 854.00K | -88.00K | -705.00K | -1.01M | 2.99M | -5.30M | -900.00K | -500.00K | 2.40M | 100.00K | 300.00K | 600.00K | 700.00K | 2.70M | -100.00K | 10.00M | 0.00 | -800.00K |
| Income Before Tax | 33.70M | 45.80M | 31.30M | 8.27M | 13.03M | 6.64M | -2.30M | -12.44M | -5.61M | -8.65M | 1.11M | -519.00K | 2.70M | -3.68M | -4.71M | -21.67M | -15.16M | -13.51M | -9.96M | -10.25M | -7.16M | -8.12M | -18.24M | -25.48M | 3.10M | 6.10M | 11.70M | 10.20M | 7.40M | 6.10M | 2.60M | -1.90M | -11.30M | 5.90M | 0.00 | -3.50M |
| Income Before Tax Ratio | 10.45% | 16.11% | 13.58% | 5.06% | 8.67% | 5.36% | -2.53% | -15.10% | -7.27% | -11.53% | 1.54% | -0.81% | 4.31% | -6.70% | -6.25% | -28.94% | -25.53% | -24.00% | -19.41% | -19.82% | -14.19% | -16.84% | -36.31% | -47.20% | 5.25% | 11.25% | 27.53% | 24.17% | 21.33% | 22.26% | 12.94% | -18.63% | -262.79% | 131.11% | 0.00% | -51.47% |
| Income Tax Expense | 12.35M | 6.80M | 6.80M | 2.35M | -1.02M | 1.67M | -157.00K | -315.00K | 928.00K | -253.00K | 716.00K | 1.24M | 1.36M | 432.00K | 1.49M | 1.52M | 843.00K | 1.54M | 1.24M | 1.06M | 1.13M | 8.96M | -3.55M | -6.58M | 900.00K | 2.00M | 4.30M | 3.30M | -100.00K | -2.20M | 100.00K | 500.00K | 100.00K | 2.60M | 800.00K | 200.00K |
| Net Income | 21.35M | 39.67M | 27.51M | 5.91M | 14.05M | 4.97M | -2.14M | -12.13M | -6.53M | -8.39M | 398.00K | -1.76M | 1.35M | 53.00K | -6.20M | -23.20M | -16.00M | -15.04M | -11.18M | -11.33M | -8.36M | -17.16M | -14.83M | -18.90M | 2.20M | 2.40M | 7.40M | 6.90M | 7.50M | 8.30M | 2.50M | -5.10M | -11.30M | 3.50M | -4.40M | -3.80M |
| Net Income Ratio | 6.62% | 13.95% | 11.94% | 3.62% | 9.35% | 4.01% | -2.36% | -14.71% | -8.47% | -11.19% | 0.55% | -2.76% | 2.15% | 0.10% | -8.23% | -30.97% | -26.95% | -26.73% | -21.78% | -21.93% | -16.56% | -35.56% | -29.53% | -35.01% | 3.73% | 4.43% | 17.41% | 16.35% | 21.61% | 30.29% | 12.44% | -50.00% | -262.79% | 77.78% | -97.78% | -55.88% |
| EPS | 0.44 | 0.83 | 0.52 | 0.13 | 0.32 | 0.11 | -0.05 | -0.30 | -0.17 | -0.22 | 0.01 | -0.05 | 0.04 | 0.00 | -0.19 | -0.79 | -0.57 | -0.60 | -0.47 | -0.58 | -0.47 | -1.00 | -0.87 | -1.23 | 0.15 | 0.18 | 0.57 | 0.50 | 0.55 | 0.84 | 0.21 | -0.50 | -1.22 | 1.44 | -1.59 | -1.52 |
| EPS Diluted | 0.43 | 0.80 | 0.50 | 0.12 | 0.30 | 0.11 | -0.05 | -0.30 | -0.17 | -0.22 | 0.01 | -0.05 | 0.04 | 0.00 | -0.19 | -0.79 | -0.57 | -0.60 | -0.47 | -0.58 | -0.47 | -1.00 | -0.87 | -1.23 | 0.15 | 0.17 | 0.53 | 0.50 | 0.55 | 0.80 | 0.20 | -0.50 | -1.22 | 1.44 | -1.59 | -1.52 |
| Weighted Avg Shares Out | 48.52M | 47.99M | 47.21M | 45.61M | 44.49M | 45.16M | 41.00M | 40.33M | 38.43M | 38.09M | 36.71M | 35.26M | 35.43M | 34.83M | 32.50M | 29.47M | 28.12M | 25.23M | 23.70M | 19.60M | 17.70M | 17.14M | 17.00M | 15.37M | 14.67M | 13.33M | 12.98M | 13.80M | 13.64M | 9.88M | 11.90M | 10.20M | 9.29M | 4.06M | 2.76M | 2.50M |
| Weighted Avg Shares Out (Dil) | 49.43M | 49.38M | 49.46M | 47.95M | 46.90M | 45.26M | 41.00M | 40.33M | 39.26M | 38.09M | 38.61M | 36.25M | 36.88M | 34.83M | 32.50M | 29.47M | 28.12M | 25.23M | 23.70M | 19.60M | 17.70M | 17.16M | 17.00M | 15.37M | 14.67M | 14.12M | 13.96M | 13.80M | 13.64M | 10.38M | 12.50M | 10.20M | 9.29M | 4.06M | 2.76M | 2.50M |
STAAR Surgical Reports Fourth Quarter and Fiscal Year 2023 Results
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today reported financial results for the fourth quarter and fiscal year...
STAAR Surgical to Report Fourth Quarter Results on February 26, 2024
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that it will release financial results for the fourth...
STAAR Surgical Announces Strategic Agreement in U.S. with SharpeVision
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, and SharpeVision, a premier ophthalmology group with clinics in Seattle, Chicago...
New Year's Insider Buying Focuses on Biotechs
As the year got underway, biotechs were in focus among the notable insider purchases.
STAAR Surgical Announces Preliminary Results for Fourth Quarter and Fiscal 2023
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL) for myopia, astigmatism and presbyopia, today announced preliminary results for the fourth quarter and fiscal year...
7 Stocks with Strong Insider Buying: December 2023
Many investors are familiar with the idea that there are many reasons why insiders sell shares, but there's only one reason they buy. Insider buying indicates a belief that a company's stock is undervalued.
See Which Inside Buyers Are Scooping Up More Shares Now
Some of the biggest insider purchases around and since the Thanksgiving holiday have come from repeat buyers.
Lilian Zhou Appointed to STAAR Surgical Board of Directors
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (ICL) for myopia, astigmatism and presbyopia, today announced the appointment of Lilian Zhou to its Board of Directors,...
STAAR Surgical to Present at Stephens Annual Investment Conference (NASH2023)
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (ICL) for myopia, astigmatism and presbyopia, today announced that management will participate in the Stephens Annual Investment Conference...
STAAR Surgical Company (STAA) Q3 2023 Earnings Call Transcript
STAAR Surgical Company (NASDAQ:STAA ) Q3 2023 Earnings Conference Call November 1, 2023 4:30 PM ET Company Participants Brian Moore - Vice President-Investor Relations & Corporate Development Tom Frinzi - President & Chief Executive Officer Patrick Williams - Chief Financial...
Source: https://incomestatements.info
Category: Stock Reports